Spruce Biosciences Inc Dossier
Qualitative Analysis
Business overview
Spruce Biosciences, Inc. (Nasdaq: SPRB) is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders and rare endocrine diseases with significant unmet medical needs. The company's lead product candidate is tralesinidase alfa enzyme replacement therapy (TA-ERT), a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU). TA-ERT is in late-stage development for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB), or Sanfilippo Syndrome Type B, a devastating and fatal pediatric neurodegenerative disorder for which there are currently no FDA-approved therapies. Following a strategic pivot, Spruce terminated its Japanese collaboration with Kaken Pharmaceutical for tildacerfont to focus its resources primarily on the clinical advancement and potential commercialization of TA-ERT.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Spruce Biosciences executed a strategic pivot to focus its resources on the development and commercialization of tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB), while winding down and exiting its Japanese tildacerfont collaboration with Kaken Pharmaceutical.
Expected impact: Aims to transition the company into a commercial-stage rare disease biopharmaceutical entity, significantly reducing operating expenses by ending tildacerfont development in certain regions.
Building out the company's commercial capabilities and executive leadership in preparation for the potential launch of TA-ERT. This includes the appointments of Dale Hooks as Chief Commercial Officer, Eric Jordan as VP of Marketing, and Tina Gullotta as VP of Finance and Corporate Controller.
Expected impact: Establishes the necessary commercial, marketing, and financial infrastructure to support a highly specialized medical affairs and commercial organization upon potential FDA approval.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of tralesinidase alfa enzyme replacement therapy (TA-ERT, previously AX 250) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The transaction included acquiring an exclusive worldwide license agreement with BioMarin Pharmaceutical Inc. for TA-ERT.
Financial impact: Transformed Spruce's pipeline, shifting focus to a near-term commercial opportunity with clinical data showing rapid and durable reduction of heparan sulfate.
Strategic Partnerships
The partnership centers around the development of SPR202 (formerly HBM9013), a potent and selective anti-corticotropin-releasing hormone monoclonal antibody for congenital adrenal hyperplasia. In January 2026, Harbour BioMed's subsidiary exercised a warrant to acquire common stock in Spruce, holding approximately 3.8% of outstanding shares, deepening the strategic alignment.
Terms: Harbour BioMed holds approximately 3.8% of Spruce's total outstanding shares (3.1% fully diluted) following the warrant exercise.